Elisabeth Bendstrup

Continous Rituximab treatment for recurrent diffuse alveolar hemorrhage in a patient with systemic lupus erythematosus and antiphosholipid syndrome

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Signe Aakjær, 5 Department of Respiratory Diseases and Allergy, Aarhus University Hospital , Aarhus, Denmark ., Institut for Klinisk Medicin - Lungemedicinsk Afdeling, NBG, Denmark
  • Elisabeth Bendstrup
  • Per Ivarsen
  • Line Bille Madsen, Aarhus University

Diffuse alveolar hemorrhage (DAH) is a rare but potentially fatal complication in systemic lupus erythematosus (SLE). DAH is typically characterized by hemoptysis, dyspnea, new infiltrates on chest x-rays or CT-scans and a drop in hemoglobin. DAH is seen in less than 2% of patients with SLE and carries a high acute mortality risk of up to 70-90%. The current treatment of DAH is high-dose intravenous corticosteroids, cyclophosphamide and extensive supportive care. Plasmapheresis is also often considered in the treatment. A few case reports have described patients with SLE and DAH in whom a single series of Rituximab (RTX), a specific anti-CD20-antigen B-cell antibody, successfully has been used to treat DAH. We here present the first case of a patient with combined SLE, antiphospholipid syndrome (APS) and recurrent DAH who was successfully controlled by continued treatment with RTX.

Original languageEnglish
JournalRespiratory medicine case reports
Pages (from-to)263-265
Number of pages3
Publication statusPublished - 2017

    Research areas

  • Journal Article

See relations at Aarhus University Citationformats

ID: 120300109